Table 2.
Clinical data at baseline and at 12, 24, 36 and 48 mo after initiation of incretin‐based therapy
| Group | 0 mo | 12 mo | 24 mo | 36 mo | 48 mo |
|---|---|---|---|---|---|
| HbAlc(%) | |||||
| lira group (liraglutide; n = 32) | 6.75 ± 0.62 | 6.40 ± 0.56** | 6.33 ± 0.72 * | 6.35 ± 0.56* | 6.26 ± 0.69* |
| sita group (sitagliptin; n = 34) | 6.72 ± 0.72 | 6.48 ± 0.66** | 6.41 ± 0.74* | 6.49 ± 0.62** | 6.55 ± 0.94** |
| lina group (linagliptin; n = 32) | 6.7 l ± 0.75 | 6.35 ± 0.56* | 6.18 ± 0.58* | 6.25 ± 0.56* | 6.21 ± 0.49* |
| BMI (kg/m2) | |||||
| lira group (liraglutide; n = 32) | 23.5 ± 3.5 | 22.8 ± 3.4 | 22.8 ± 3.2 | 22.7 ± 3.1 | 23.1 ± 3.2 |
| sita group (sitagliptin; n = 34) | 24.2 ± 4.2 | 24.1 ± 4.2 | 24.2 ± 4.2 | 24.3 ± 4.2 | 24.3 ± 4.3 |
| lina group (linagliptin; n = 32) | 23.8 ± 4.8 | 23.0 ± 4.6 | 22.8 ± 4.6 | 22.6 ± 4.8 | 23.2 ± 4.6 |
| BNP (pg/mL) | |||||
| lira group (liraglutide; n | 91.6 ± 69.9 | 61.2 ± 49.4* | 58.8 ± 46.1* | 55.8 ± 46.2* | 65.8 ± 50.9* |
| sita group (sitagliptin; n = 34) | 83.9 ± 59.2 | 66.1 ± 50.7* | 64.4 ± 48.3* | 76.8 ± 53.5 | 73.3 ± 47.2 |
| lina group (linagliptin; n = 32) | 90.6 ± 58.6 | 76.8 ± 56.2 | 70.8 ± 53.0* | 78.3 ± 51.1 | 71.8 ± 46.5* |
| β2MG (mg/dL) | |||||
| lira group (liraglutide; n = 32) | 4.9 ± 3.2 | 4.5 ± 2.4 | 4.6 ± 2.7 | 4.7 ± 2.8 | 4.8 ± 2.7 |
| sita group (sitagliptin; n = 34) | 4.5 ± 4.2 | 4.5 ± 3.4 | 4.4 ± 3.7 | 4.5 ± 3.6 | 4.6 ± 4.4 |
| lina group (linagliptin; n = 32) | 4.6 ± 4.5 | 4.4 ± 3.7 | 4.4 ± 3.8 | 4.6 ± 3.4 | 4.7 ± 4.2 |
| CRP (mg/dL) | |||||
| lira group (liraglutide; n = 32) | 0.26 ± 0.21 | 0.12 ± 0.13 | 0.19 ± 0.10 | 0.08 ± 0.09 | 0.09 ± 0.05 |
| sita group (sitagliptin; n = 34) | 0.22 ± 0.30 | 0.13 ± 0.17 | 0.16 ± 0.20 | 0.15 ± 0.19 | 0.13 ± 0.14 |
| lina group (linagliptin; n = 32) | 0.24 ± 0.18 | 0.17 ± 0.11 | 0.16 ± 0.11*** | 0.17 ± 0.11*** | 0.16 ± 0.11*** |
| UA (mg/dL) | |||||
| lira group (liraglutide; n = 32) | 6.7 ± 2.5 | 6.3 ± 1.9 | 6.3 ± 1.7 | 6.2 ± 1.8 | 6.0 ± 1.6 |
| sita group (sitagliptin; n = 34) | 6.3 ± 1.1 | 6.2 ± 1.0 | 6.2 ± 1.0 | 6.1 ± 1.2 | 6.1 ± 1.1 |
| lina group (linagliptin; n = 32) | 6.7 ± 2.0 | 6.3 ± 2.1 | 6.3 ± 1.7 | 6.0 ± 1.5 | 5.9 ± 1.3 |
| LDL‐C (mg/dL) | |||||
| lira group (liraglutide; n = 32) | 125.5 ± 27.4 | 109.1 ± 36.5 | 105.9 ± 27.5* | 93.5 ± 25.3* | 103.2 ± 20.8** |
| sita group (sitagliptin; n = 34) | 100.9 ± 40.7 | 94.2 ± 28.3 | 97.7 ± 28.1 | 95.8 ± 30.2 | 91.6 ± 26.9 |
| lina group (linagliptin; n = 32) | 115.8 ± 29.5 | 102.2 ± 26.9 | 91.3 ± 29.9 | 91.2 ± 25.8* | 91.5 ± 27.8 |
| HDL‐C (mg/dL) | |||||
| lira group (liraglutide; n = 32) | 51.9 ± 14.6 | 50.3 ± 14.5 | 50.0 ± 14.4 | 51.6 ± 15.7 | 51.6 ± 14.0 |
| sita group (sitagliptin; n = 34) | 51.2 ± 11.4 | 49.8 ± 12.8 | 49.0 ± 11.4 | 50.7 ± 11.4 | 52.4 ± 12.7 |
| lina group (linagliptin; n = 32) | 51.0 ± 18.2 | 49.1 ± 14.6 | 51.8 ± 13.6 | 50.2 ± 17.0 | 53.0 ± 14.9 |
Data are expressed as means ± standards deviations.
BMI, body mass index; BNP, brain natriuretic peptide; CRP, C‐reactive protein; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; UA, uric acid; β2 MG, β2 microgloburin.
*P < 0.01, **P < 0.05 vs baseline, ***P < 0.05 vs lira group.